Q4 2025 Madrigal Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Madrigal Pharmaceuticals Inc (MDGL) achieved nearly $1 billion in net sales for Rezdiffra in its first full year on the market, establishing it as the foundational therapy in MASH.
- The US MASH market has grown nearly 50% since the end of 2023, with expectations for continued double-digit growth.
- Rezdiffra's patent exclusivity has been extended to 2045, providing a long runway for sustained market presence.
- The company has built a robust pipeline with more than 10 programs, including an oral GLP-1, a late-stage DGAT-2 inhibitor, and six preclinical siRNA targets.
- Madrigal Pharmaceuticals Inc (MDGL) has successfully initiated its ex-US rollout, starting in Germany, and continues to expand its market presence.
- The contribution from the Germany launch to worldwide revenues and patient numbers was negligible in 2025, with limited expectations for 2026.
- Gross to net impact is expected to increase to the high 30% range in 2026, which may affect net sales growth.
- The company faces challenges in maintaining high persistence and adherence rates, with current rates around 60%-70%, despite some institutions reporting up to 90%.
- There is uncertainty regarding the evolution of the ex-US market, particularly with the impact of MFN (Most Favored Nation) pricing.
- The company needs to navigate the complexities of developing combination therapies and ensuring they provide meaningful benefits without diminishing returns.
Good morning, and thank you for standing by. Welcome to Madrigal Pharmaceuticals' fourth quarter and full year 2025 earnings conference call. (Operator Instructions)
As a reminder, today's conference call is being recorded. I would now like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahead.
Thank you, Michelle. Good morning, everyone, and thank you for joining us to discuss Madrigal's fourth quarter and full year 2025 earnings. We issued a press release this morning and posted a slide deck to accompany this webcast on the Investor Relations section of our website.
On the call with me today is Bill Sibold, Chief Executive Officer; David Soergel, Chief Medical Officer; and Mardi Dier, Chief Financial Officer. They will provide prepared remarks, followed by Q&A. Please note on slide 2, we will be making certain forward-looking statements today. We refer you to our SEC filings for a discussion of the risks that may cause actual results
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
